利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.022 秒)

    Antibodies That Bind To OX40 and Their Uses
    1.
    发明申请
    Antibodies That Bind To OX40 and Their Uses 审中-公开

    公开(公告)号：US20200071409A1

    公开(公告)日：2020-03-05

    申请号：US16298289

    申请日：2019-03-11

    申请人： GLENMARK PHARMACEUTICALS S.A.

    发明人： Antoine ATTINGER ,  Stanislas BLEIN ,  Jonathan Albert BACK ,  Rami LISSILAA ,  Samuel HOU

    IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395

    摘要： The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

    ANTIBODIES THAT BIND TO OX40 AND THEIR USES
    2.
    发明申请
    ANTIBODIES THAT BIND TO OX40 AND THEIR USES 审中-公开
    绑定到OX40的抗体及其使用

    公开(公告)号：US20140294824A1

    公开(公告)日：2014-10-02

    申请号：US14222421

    申请日：2014-03-21

    申请人： GLENMARK PHARMACEUTICALS S.A.

    发明人： Antoine ATTINGER ,  Stanislas Blein ,  Jonathan Albert Back ,  Rami Lissilaa ,  Samuel Hou

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N2333/70578

    摘要： The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

    摘要翻译： 本发明涉及与人OX40结合的拮抗剂抗体或其片段。 更具体地，本发明涉及与人OX40结合的拮抗剂抗体或其片段，其包含包含SEQ ID NO：1的氨基酸序列的重链CDR1和/或包含SEQ ID NO：1的氨基酸序列的重链CDR2 ID NO：2，和/或包含SEQ ID NO：3的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO：4的氨基酸序列的轻链CDR1和/或包含SEQ ID NO：5的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO：6。

    ANTIBODIES THAT BIND TO TL1A AND THEIR USES
    3.
    发明申请
    ANTIBODIES THAT BIND TO TL1A AND THEIR USES 审中-公开

    公开(公告)号：US20200079863A1

    公开(公告)日：2020-03-12

    申请号：US16437550

    申请日：2019-06-11

    申请人： Glenmark Pharmaceuticals S.A.

    发明人： Antoine ATTINGER ,  Jonathan Albert BACK ,  Stanislas BLEIN ,  Rami LISSILAA ,  Darko SKEGRO

    IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K39/395

    摘要： The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.